A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma

Bone Marrow Transplantation

Volumn 20, Issue 10, 1997, Pages 847-853

  Weaver, C H ^a   Greco, F A ^a   Hainsworth, J D ^a   Zhen, B ^a   Baldwin, P ^a   Wittlin, F ^a   Lewis, M ^a   West, W H ^a   Schwartzberg, L ^a   Buckner, C D ^a,b  

^a Clin Res Div Response Oncol I   (United States)

^b Response Oncology Inc   (United States)

Author keywords

Carboplatin; High dose melphalan; Mitoxantrone

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; MELPHALAN; MITOXANTRONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; HEART ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROLOGIC DISEASE; OVARY CARCINOMA; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VOMITING;

EID: 0030777571     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700976     Document Type: Article

References (41)

1. Thigpen JT, Bertelsen K, Eisenhauer EA et al. Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy (review). Ann Oncol 1993; 4: 35-40.
2. Kawai M, Kikkawa F, Hattori S et al. Long-term follow-up of patients with epithelial carcinoma of the ovary. Int J Gynaecol Obster 1994; 44: 259-266.
3. Del Campo JM, Felip E, Rubio D et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol 1994; 53: 27-32.
4. Kaye SB, Paul J, Cassidy J et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996; 14: 2113-2119.
5. Hainsworth JD, Grosh WW, Burnett LS et al. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med 1988; 108: 165-170.
6. Ozols RF. Carboplutin and taxol (paclitaxel) in advanced ovarian carcinoma. Ann oncol 1994; 5: S39-S43.
7. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 1996; 334: 1-6.
8. Cannistra SA. Cancer of the ovary. New Engl J Med 1993; 329: 1550-1559.
9. Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987; 5: 756-767.
10. McGuire WP, Hoskins WJ, Brady MF et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995; 13: 1589-1599.
11. Ngan HY, Choo YC, Cheung M et al. A randomized study of high-dose vs low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 1989; 35: 221-227.
12. Ehrlich CE, Einhorn L, Stehman FB. Treatment of advanced epithelial ovarian cancer using cisplatin, adriamycin and cytoxan - the Indiana University experience. Clin Obstet Gynaecol 1983; 10: 325-335.
13. Shpall EJ, Clarke-Pearson D, Soper JT et al. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 1990; 38: 386-391.
14. Mulder PO, Willemse PH, Aalders JG et al. High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Ear J Cancer Clin Oncol 1989; 25: 645-649.
15. Ellis ED, Williams SF, Moormeier JA et al. A phase I-II study of high-dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies. Bone Marrow Transplant 1990; 6: 439-442.
16. Lazarus HM, Herzig RH, Graham-Pole J. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983; 1: 359-367.
17. Corringham R, Gilmore M, Prentice H. High-dose melphalan with autologous bone marrow transplant: treatment of poor prognosis tumors. Cancer 1983; 52: 1783-1787.
18. Viens P, Maraninchi D, Legros M et al. High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 1990; 5: 227-233.
19. Viens P, Maraninchi D. High-dose chemotherapy and autologous marrow transplantation for common epithelial ovarian carcinoma. In: Armitage JO, Antman KH (eds). High-dose Cancer Therapy (Pharmacology, Hematopoietins, Stem Cells). Williams & Wilkins: Baltimore, 1992, pp 729-734.
20. Stiff PJ, McKenzie RS, Alberts DS et al. Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. J Clin Oncol 1994; 12: 176-183.
21. Stiff P, Bayer R, Camarda M et al. A phase II trial of high-dose mitoxantrone, carboplatin and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: analysis of risk factors for clinical outcome. Gynecol Oncol 1995; 57: 278-285.
22. Dauplat J, Legros M, Condat P et al. High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation. Gynecol Oncol 1989; 34: 294-298.
23. Extra JM, Cure H, Viens P et al. High dose chemotherapy with autologous bone marrow transplantation in ovarian adenocarcinoma. Bull Cancer 1993; 80: 156-162.
24. Benedetti-Panici P, Greggi S, Scambia G et al. High-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancer. Ann Med 1995; 27: 133-138.
25. Ozols RF, Behrens BC, Ostchega Y, Young RC. High-dose cisplatin and high-dose carboplatin in refractory ovarian cancer. Cancer Treat Rev 1985; 12: 59-65.
26. Shea TC, Flaherty M, Elias A et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989; 7: 651-661.
27. Muss HB, Asbury R, Bundy B et al. Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1984; 7: 737-739.
28. Hilgers RD, Rivkin SE, Von Hoff DD, Alberts DS. Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study. Am J Clin Oncol 1984; 7: 499-501.
29. Lawton F, Blackledge G, Mould J et al. Phase II study of mitoxantrone in epithelial ovarian cancer. Cancer Treat Rep 1987; 71: 627-629.
30. Alberts DS, Young L, Mason N, Salmon SE. In vitro evaluation of anticancer drugs against ovarian cancer at concen-trations achievable by intraperitoneal administration. Semin Oncol 1985; 12: 38-42.
31. Alberts DS, Surwit EA, Peng YM et al. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res 1988; 48: 5874-5877.
32. Markman M, Hakes T, Reichman B et al. Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer. J Clin Oncol 1991; 9: 978-982.
33. Ayash L, Korbut T, Herman TS, Teicher BA. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells. Cancer Lett 1991; 61: 7-14.
34. Mulder PO, Sleijfer DT, Willemse PH et al. High-dose cyclo-phosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 1989; 49: 4654-4658.
35. Schwartzberg L, Birch R, Hazelton B et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. J Hematother 1992; 1: 317-327.
36. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
37. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10: 239-253.
38. Crawford SW. Critical care and respiratory failure. In: Thomas ED, Forman SJ, Blume K (eds). Bone Marrow Transplant. Blackwell Scientific Publications: Boston, 1994, pp 513-526.
39. Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary (review). Cancer 1993; 71: 1559-1564.
40. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
41. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.